Mariella Vieira Pereira Leão
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Mariella Vieira Pereira Leão has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Luciane Dias de Oliveira
Department of Bioscience and Oral Diagnosis, Institute of Science and Technology, São José dos Campos, São Paulo State University (UNESP), São Paulo 12245-000, Brazil
6 shared publications - Silvana Soléo Ferreira dos Santos
Universidade de Taubaté, Brazil
6 shared publications Antonio Olavo Cardoso Jorge
Universidade Estadual Paulista, Brazil
5 shared publicationsCélia Regina Gonçalves e Silva
Instituto Básico de Biociências, Universidade de Taubaté, Taubaté, SP, BR
4 shared publications- Fernando Callera
Humanitas
4 shared publications - Mariana Araujo Mendes Silva
Faculdade de Ciências Medicas de São José dos Campos
4 shared publications
Latest Publications
- Open Access
- 3 February 2025
- Published by Associacao Brasileira de Transplantes de Orgaos in Brazilian Journal of Transplantation
- Vol. 28 (1)
Biomarkers for Graft-Versus-Host Disease in Hematopoietic Stem Cell Transplant Patients
Introduction: One of the therapeutic strategies for hematological malignancies is hematopoietic stem cell transplantation (HSCT). However, a common and severe post-transplantation complication is graft-versus-host disease (GVHD), primarily mediated by the donor’s immunocompetent cells, particularly T lymphocytes. Objectives: This study aims to explore potential biomarkers for the prognosis and diagnosis of GVHD following HSCT. Methods: This integrative review was conducted using the PubMed and Google Scholar databases. The research question was structured and refined using the PICO (Population, Intervention, Comparison, and Outcome) method, resulting in the guiding question: “Can biomarkers help in the diagnosis, prognosis, and treatment of GVHD?” The descriptors used were: “graft versus host disease,” “hematopoietic stem cell transplant,” and “microRNAs,” combined with the Boolean operator “AND.” These searches resulted in 1,942 articles, from which 33 were selected based on the English language and relevance to the main objectives of the study, after reviewing their titles and abstracts. Results: Among the biomarkers examined, microRNAs emerge as the most promising due to their stability and ease of extraction from body fluids. While some progress has been made in identifying such markers in recent years, further research is necessary to enhance understanding and ensure their practical application in clinical settings. Conclusion: The importance of finding biomarkers, considered more enlightening and less susceptible to bias compared to traditional diagnostic methods that can predict the risk of GVHD, is demonstrated. Although there are strategies to reduce the risk of developing this complication, such as T lymphocyte depletion, patients undergoing these therapies have a high risk of relapse since the effect called “graft-versus-leukemia” is compromised. Although the search for such markers has achieved some success in recent years, further studies are needed to provide additional clarification and ensure applicability in daily clinical practice. An ideal biomarker should be easily measurable, highly sensitive, and specific, enabling early detection using readily available samples.
- 3 February 2025
- Published by Associacao Brasileira de Transplantes de Orgaos in Brazilian Journal of Transplantation
- Vol. 28 (1)
Open AccessBiomarkers for Graft-Versus-Host Disease in Hematopoietic Stem Cell Transplant Patients
Introduction: One of the therapeutic strategies for hematological malignancies is hematopoietic stem cell transplantation (HSCT). However, a common and severe post-transplantation complication is graft-versus-host disease (GVHD), primarily mediated by the donor’s immunocompetent cells, particularly T lymphocytes. Objectives: This study aims to explore potential biomarkers for the prognosis and diagnosis of GVHD following HSCT. Methods: This integrative review was conducted using the PubMed and Google Scholar databases. The research question was structured and refined using the PICO (Population, Intervention, Comparison, and Outcome) method, resulting in the guiding question: “Can biomarkers help in the diagnosis, prognosis, and treatment of GVHD?” The descriptors used were: “graft versus host disease,” “hematopoietic stem cell transplant,” and “microRNAs,” combined with the Boolean operator “AND.” These searches resulted in 1,942 articles, from which 33 were selected based on the English language and relevance to the main objectives of the study, after reviewing their titles and abstracts. Results: Among the biomarkers examined, microRNAs emerge as the most promising due to their stability and ease of extraction from body fluids. While some progress has been made in identifying such markers in recent years, further research is necessary to enhance understanding and ensure their practical application in clinical settings. Conclusion: The importance of finding biomarkers, considered more enlightening and less susceptible to bias compared to traditional diagnostic methods that can predict the risk of GVHD, is demonstrated. Although there are strategies to reduce the risk of developing this complication, such as T lymphocyte depletion, patients undergoing these therapies have a high risk of relapse since the effect called “graft-versus-leukemia” is compromised. Although the search for such markers has achieved some success in recent years, further studies are needed to provide additional clarification and ensure applicability in daily clinical practice. An ideal biomarker should be easily measurable, highly sensitive, and specific, enabling early detection using readily available samples.
- Open Access
- 3 February 2025
- Published by Associacao Brasileira de Transplantes de Orgaos in Brazilian Journal of Transplantation
- Vol. 28 (1)
Biomarcadores para Doença do Enxerto Contra Hospedeiro em Pacientes Transplantados com Células-Tronco Hematopoiéticas
Introdução: Uma das estratégias terapêuticas para neoplasias hematológicas é o transplante de células-tronco hematopoiéticas. No entanto, uma complicação comum e grave pós-transplante é a doença do enxerto contra hospedeiro, mediada principalmente pelas células imunocompetentes do doador, particularmente os linfócitos T. Objetivos: Este estudo tem como objetivo explorar potenciais biomarcadores para o prognóstico e diagnóstico da doença do enxerto contra hospedeiro após o transplante de células-tronco hematopoiéticas. Métodos: Trata-se de uma revisão integrativa realizada nas bases de dados PubMed e Google Acadêmico. A questão de pesquisa foi estruturada e refinada utilizando o método PICO (Population, Intervention, Comparison, and Outcome), resultando na seguinte questão norteadora: “Os biomarcadores podem auxiliar no diagnóstico, prognóstico e tratamento da DECH?” Foram utilizados os descritores: “doença do enxerto contra hospedeiro”, “transplante de células-tronco hematopoéticas” e “microRNAs” combinados com o operador booleano “AND”. Essas buscas resultaram em 1.942 artigos, dos quais 33 foram selecionados com base no idioma inglês e na relevância para os objetivos principais do estudo, após revisão de seus títulos e resumos. Resultados: Entre os biomarcadores examinados, os microRNAs surgem como os mais promissores devido à sua estabilidade e facilidade de extração de fluidos corporais. Embora nos últimos anos tenha havido algum sucesso na identificação de tais marcadores, mais pesquisas são essenciais para melhorar a compreensão e garantir a sua aplicação prática em ambientes clínicos. Conclusão: Demonstra-se a importância de encontrar biomarcadores, considerados mais esclarecedores e menos suscetíveis a vieses em relação aos métodos diagnósticos tradicionais, que possam prever o risco da doença do enxerto contra hospedeiro. Embora existam estratégias que reduzam o risco de desenvolvimento dessa complicação, como a depleção de linfócitos T, os pacientes submetidos a essas terapias apresentam alto risco de recidiva, uma vez que o efeito denominado “enxerto versus leucemia” fica comprometido. Embora a busca por tais marcadores tenha alcançado algum sucesso nos últimos anos, mais estudos são necessários para fornecer maiores esclarecimentos e garantir a aplicabilidade na prática clínica diária. Um biomarcador ideal deve ser facilmente medido, ter alta sensibilidade e especificidade e permitir a detecção precoce a partir de amostras prontamente disponíveis.
- 3 February 2025
- Published by Associacao Brasileira de Transplantes de Orgaos in Brazilian Journal of Transplantation
- Vol. 28 (1)
Open AccessBiomarcadores para Doença do Enxerto Contra Hospedeiro em Pacientes Transplantados com Células-Tronco Hematopoiéticas
Introdução: Uma das estratégias terapêuticas para neoplasias hematológicas é o transplante de células-tronco hematopoiéticas. No entanto, uma complicação comum e grave pós-transplante é a doença do enxerto contra hospedeiro, mediada principalmente pelas células imunocompetentes do doador, particularmente os linfócitos T. Objetivos: Este estudo tem como objetivo explorar potenciais biomarcadores para o prognóstico e diagnóstico da doença do enxerto contra hospedeiro após o transplante de células-tronco hematopoiéticas. Métodos: Trata-se de uma revisão integrativa realizada nas bases de dados PubMed e Google Acadêmico. A questão de pesquisa foi estruturada e refinada utilizando o método PICO (Population, Intervention, Comparison, and Outcome), resultando na seguinte questão norteadora: “Os biomarcadores podem auxiliar no diagnóstico, prognóstico e tratamento da DECH?” Foram utilizados os descritores: “doença do enxerto contra hospedeiro”, “transplante de células-tronco hematopoéticas” e “microRNAs” combinados com o operador booleano “AND”. Essas buscas resultaram em 1.942 artigos, dos quais 33 foram selecionados com base no idioma inglês e na relevância para os objetivos principais do estudo, após revisão de seus títulos e resumos. Resultados: Entre os biomarcadores examinados, os microRNAs surgem como os mais promissores devido à sua estabilidade e facilidade de extração de fluidos corporais. Embora nos últimos anos tenha havido algum sucesso na identificação de tais marcadores, mais pesquisas são essenciais para melhorar a compreensão e garantir a sua aplicação prática em ambientes clínicos. Conclusão: Demonstra-se a importância de encontrar biomarcadores, considerados mais esclarecedores e menos suscetíveis a vieses em relação aos métodos diagnósticos tradicionais, que possam prever o risco da doença do enxerto contra hospedeiro. Embora existam estratégias que reduzam o risco de desenvolvimento dessa complicação, como a depleção de linfócitos T, os pacientes submetidos a essas terapias apresentam alto risco de recidiva, uma vez que o efeito denominado “enxerto versus leucemia” fica comprometido. Embora a busca por tais marcadores tenha alcançado algum sucesso nos últimos anos, mais estudos são necessários para fornecer maiores esclarecimentos e garantir a aplicabilidade na prática clínica diária. Um biomarcador ideal deve ser facilmente medido, ter alta sensibilidade e especificidade e permitir a detecção precoce a partir de amostras prontamente disponíveis.
- Open Access
- 5 September 2024
- Published by MDPI AG in Dentistry Journal
- Vol. 12 (9) , 286
In Vitro Evaluation of Sodium Hypochlorite, Chlorhexidine, Propolis, and Calcium Hydroxide Effect on Lipoteichoic-Acid-Induced Proinflammatory Cytokines Production
This study aimed to evaluate the effects of sodium hypochlorite (NaOCl), chlorhexidine (CHX), and the glycolic extract of propolis (GEP) as endodontic irrigants and of calcium hydroxide [Ca(OH)2], CHX, or Ca(OH)2 + CHX as intracanal medications on the capacity of the lipoteichoic acid (LTA) of Enterococcus faecalis in macrophages’ proinflammatory cytokines production. Freshly extracted 108 human single-rooted teeth were used in this study. The LTA of E. faecalis was standardized in double-distilled pyrogen-free water (250 µg/mL) and inoculated into the specimens subdivided into nine subgroups (n = 12). Cultures of murine macrophages (RAW 264.7) were treated with 30 µL of each sample collected from root canals and incubated (37 °C, 5% CO2) for 24 h. Lastly, anti-TNF-α, anti-IL-6, anti-IP-10, anti-MIP-1α, anti-G-CSF, and anti-IL-1β DuoSet kits were used to perform an ELISA assay. Data were analyzed using one-way ANOVA and Tukey test (p ≥ 0.05). It was found that 1% NaOCl was the most effective irrigant in reducing the capacity of LTA in cytokines production, followed by 12% GEP and 2% CHX, respectively. Ca(OH)2 + CHX presented the best results when associated with NaOCl or GEP. Thus, NaOCl or GEP associated with Ca(OH)2 + CHX were effective in reducing the capacity of LTA in different macrophages pro-inflammatory cytokines production.
- 5 September 2024
- Published by MDPI AG in Dentistry Journal
- Vol. 12 (9) , 286
Open AccessIn Vitro Evaluation of Sodium Hypochlorite, Chlorhexidine, Propolis, and Calcium Hydroxide Effect on Lipoteichoic-Acid-Induced Proinflammatory Cytokines Production
This study aimed to evaluate the effects of sodium hypochlorite (NaOCl), chlorhexidine (CHX), and the glycolic extract of propolis (GEP) as endodontic irrigants and of calcium hydroxide [Ca(OH)2], CHX, or Ca(OH)2 + CHX as intracanal medications on the capacity of the lipoteichoic acid (LTA) of Enterococcus faecalis in macrophages’ proinflammatory cytokines production. Freshly extracted 108 human single-rooted teeth were used in this study. The LTA of E. faecalis was standardized in double-distilled pyrogen-free water (250 µg/mL) and inoculated into the specimens subdivided into nine subgroups (n = 12). Cultures of murine macrophages (RAW 264.7) were treated with 30 µL of each sample collected from root canals and incubated (37 °C, 5% CO2) for 24 h. Lastly, anti-TNF-α, anti-IL-6, anti-IP-10, anti-MIP-1α, anti-G-CSF, and anti-IL-1β DuoSet kits were used to perform an ELISA assay. Data were analyzed using one-way ANOVA and Tukey test (p ≥ 0.05). It was found that 1% NaOCl was the most effective irrigant in reducing the capacity of LTA in cytokines production, followed by 12% GEP and 2% CHX, respectively. Ca(OH)2 + CHX presented the best results when associated with NaOCl or GEP. Thus, NaOCl or GEP associated with Ca(OH)2 + CHX were effective in reducing the capacity of LTA in different macrophages pro-inflammatory cytokines production.
- Open Access
- 3 July 2024
- Published by Sociedade de Pediatria do Estado do Rio de Janeiro in Revista de Pediatria SOPERJ
- Vol. 25 (1) , e20250319-26
Leite materno: um alimento probiótico
Introdução: Sabe-se que o leite materno é o alimento essencial ao recém-nascido até, pelo menos, seus seis meses de vida. Dentre outras substâncias, o leite materno apresenta microrganismos, que quando presentes em quantidades adequadas, conferem benefícios à saúde do bebê. Objetivos: Correlacionar a presença de microrganismos no leite materno com os benefícios à saúde do recém-nascido/lactente, atribuindo características probióticas a esse alimento. Metodologia: Assim, o presente trabalho revisou a literatura, selecionando trabalhos disponíveis na plataforma PubMed que explorassem a composição e os benefícios desse alimento, bem como suas propriedades probióticas. Síntese de dados: Observou-se que os gêneros de bactérias Lactobacillus e Bifidobacterium, amplamente conhecidos como probióticos, são encontrados no leite materno, e que a composição do leite influencia suas presenças. A composição, por sua vez, pode ser influenciada pelo estilo de vida materno, incluindo a incidência de psicopatologias como depressão, ansiedade e estresse. Conclusão: Concluiu-se que, incontestavelmente, o leite materno pode ser considerado um alimento probiótico, com a vantagem do fácil acesso e nenhum custo, tornando-se a melhor alternativa para nutrir e promover a saúde do recém-nascido.
- 3 July 2024
- Published by Sociedade de Pediatria do Estado do Rio de Janeiro in Revista de Pediatria SOPERJ
- Vol. 25 (1) , e20250319-26
Open AccessLeite materno: um alimento probiótico
Introdução: Sabe-se que o leite materno é o alimento essencial ao recém-nascido até, pelo menos, seus seis meses de vida. Dentre outras substâncias, o leite materno apresenta microrganismos, que quando presentes em quantidades adequadas, conferem benefícios à saúde do bebê. Objetivos: Correlacionar a presença de microrganismos no leite materno com os benefícios à saúde do recém-nascido/lactente, atribuindo características probióticas a esse alimento. Metodologia: Assim, o presente trabalho revisou a literatura, selecionando trabalhos disponíveis na plataforma PubMed que explorassem a composição e os benefícios desse alimento, bem como suas propriedades probióticas. Síntese de dados: Observou-se que os gêneros de bactérias Lactobacillus e Bifidobacterium, amplamente conhecidos como probióticos, são encontrados no leite materno, e que a composição do leite influencia suas presenças. A composição, por sua vez, pode ser influenciada pelo estilo de vida materno, incluindo a incidência de psicopatologias como depressão, ansiedade e estresse. Conclusão: Concluiu-se que, incontestavelmente, o leite materno pode ser considerado um alimento probiótico, com a vantagem do fácil acesso e nenhum custo, tornando-se a melhor alternativa para nutrir e promover a saúde do recém-nascido.
- Open Access
- 18 March 2024
- Published by Universidade de São Paulo. Agência de Bibliotecas e Coleções Digitais in Revista de Medicina
- Vol. 103 (1)
O papel paradoxal de Lactobacillus na saúde
O gênero Lactobacillus faz parte da microbiota normal, mas está relacionado a uma variedade de infecções humanas, como abscessos dentários, bacteremia, colecistite, empiema, endocardite, meningite, peritonite, infecção protética do joelho e pielonefrite. Paradoxalmente, há evidências da eficácia da utilização dos Lactobacillus sob a forma de probióticos para prevenção e tratamento de doenças diarréicas e inflamatórias intestinais, vaginoses bacterianas, infecções do trato urinário e respiratório e até mesmo cárie dentária. O presente trabalho objetivou demonstrar e discutir esses contraditórios papéis do gênero Lactobacillus. Para isso, foram selecionados relatos de caso, ensaios clínicos, revisões da literatura e metanálises, dos últimos 30 anos, utilizando-se as palavras-chaves: Lactobacillus, Probiotics, Dental Caries, Diseases and Health. Os diferentes estudos demonstraram que os efeitos dos probióticos podem ser específicos de cada cepa e que a cepa mais efetiva para cada quadro clínico, sua dose ideal, sua melhor forma de administração e melhor momento de utilização ainda são questionáveis. Além disso, a existência de uma comorbidade ou condição suscetível pré existente no paciente aumenta o risco de infecções por lactobacilos. Assim, concluiu-se que, somente após uma investigação cuidadosa da cepa de Lactobacillus e do paciente, das suas condições bucais e gerais, os probióticos contendo esses microrganismos poderiam ser utilizados de forma mais segura, benéfica e eficaz.
- 18 March 2024
- Published by Universidade de São Paulo. Agência de Bibliotecas e Coleções Digitais in Revista de Medicina
- Vol. 103 (1)
Open AccessO papel paradoxal de Lactobacillus na saúde
O gênero Lactobacillus faz parte da microbiota normal, mas está relacionado a uma variedade de infecções humanas, como abscessos dentários, bacteremia, colecistite, empiema, endocardite, meningite, peritonite, infecção protética do joelho e pielonefrite. Paradoxalmente, há evidências da eficácia da utilização dos Lactobacillus sob a forma de probióticos para prevenção e tratamento de doenças diarréicas e inflamatórias intestinais, vaginoses bacterianas, infecções do trato urinário e respiratório e até mesmo cárie dentária. O presente trabalho objetivou demonstrar e discutir esses contraditórios papéis do gênero Lactobacillus. Para isso, foram selecionados relatos de caso, ensaios clínicos, revisões da literatura e metanálises, dos últimos 30 anos, utilizando-se as palavras-chaves: Lactobacillus, Probiotics, Dental Caries, Diseases and Health. Os diferentes estudos demonstraram que os efeitos dos probióticos podem ser específicos de cada cepa e que a cepa mais efetiva para cada quadro clínico, sua dose ideal, sua melhor forma de administração e melhor momento de utilização ainda são questionáveis. Além disso, a existência de uma comorbidade ou condição suscetível pré existente no paciente aumenta o risco de infecções por lactobacilos. Assim, concluiu-se que, somente após uma investigação cuidadosa da cepa de Lactobacillus e do paciente, das suas condições bucais e gerais, os probióticos contendo esses microrganismos poderiam ser utilizados de forma mais segura, benéfica e eficaz.
- Open Access
- 25 January 2023
- Published by Associacao Brasileira de Transplantes de Orgaos in Brazilian Journal of Transplantation
- Vol. 26 (1)
Prophylaxis of Fungal Infections in Transplant Patients:What has Changed in Recent Years?
Objective: The present work aimed to review the invasive fungal infections (IFIs) and antifungal prophylaxis used in the last 20 years in transplant patients to identify the changes that occurred in this period and discuss the most current conducts. Methods: This is a systematic review in which the PubMed database was used, in which scientific articles from the last 20 years were selected, covering clinical trials, randomized controlled trials, systematic reviews of the literature and meta-analyses. Results: According to the present study, posaconazole and voriconazole are the antifungal drugs of choice for IFI prophylaxis in hematopoietic stem cell transplantation (HSCT). However, as posaconazole is not available in the public health system in Brazil, the most viable option remains voriconazole. Regarding IFI prophylaxis in solid organ transplantation (SOT), it was observed that there are variations depending on the transplanted target organ, and there is no evidence of its need in kidney transplantation. Although azoles are also the most used and bring clear benefits in liver and lung transplantation, some current studies have placed echinocandins on the same level, encouraging their use to prevent IFI in these patients. Conclusion: In the last five years, there has been a great shortage of clinical trials comparing different antifungal prophylaxis. New studies are needed to establish the most appropriate protocols for each condition and profile of the transplanted patient.
- 25 January 2023
- Published by Associacao Brasileira de Transplantes de Orgaos in Brazilian Journal of Transplantation
- Vol. 26 (1)
Open AccessProphylaxis of Fungal Infections in Transplant Patients:What has Changed in Recent Years?
Objective: The present work aimed to review the invasive fungal infections (IFIs) and antifungal prophylaxis used in the last 20 years in transplant patients to identify the changes that occurred in this period and discuss the most current conducts. Methods: This is a systematic review in which the PubMed database was used, in which scientific articles from the last 20 years were selected, covering clinical trials, randomized controlled trials, systematic reviews of the literature and meta-analyses. Results: According to the present study, posaconazole and voriconazole are the antifungal drugs of choice for IFI prophylaxis in hematopoietic stem cell transplantation (HSCT). However, as posaconazole is not available in the public health system in Brazil, the most viable option remains voriconazole. Regarding IFI prophylaxis in solid organ transplantation (SOT), it was observed that there are variations depending on the transplanted target organ, and there is no evidence of its need in kidney transplantation. Although azoles are also the most used and bring clear benefits in liver and lung transplantation, some current studies have placed echinocandins on the same level, encouraging their use to prevent IFI in these patients. Conclusion: In the last five years, there has been a great shortage of clinical trials comparing different antifungal prophylaxis. New studies are needed to establish the most appropriate protocols for each condition and profile of the transplanted patient.
- Open Access
- 25 January 2023
- Published by Associacao Brasileira de Transplantes de Orgaos in Brazilian Journal of Transplantation
- Vol. 26 (1)
Profilaxia de Infecções Fúngicas em Pacientes Transplantados: O que Mudou nos Últimos Anos?
Objetivo: O presente trabalho objetivou revisar as infecções fúngicas invasivas (IFIs) e as profilaxias antifúngicas utilizadas nos últimos 20 anos em pacientes transplantados, de forma a identificar as mudanças ocorridas nesse período e discutir as condutas mais atuais. Métodos: Trata-se de uma revisão sistemática em que se utilizou a base de dados PubMed, na qual foram selecionados artigos científicos dos últimos 20 anos, abrangendo ensaios clínicos, ensaios controlados randomizados, revisões sistemáticas da literatura e metanálises. Resultados: De acordo com o presente estudo, o posaconazol e o voriconazol parecem ser as drogas antifúngicas de escolha na profilaxia de IFI em transplante de células-tronco hematopoiéticas (TCTH). Entretanto, como não há disponibilidade do posaconazol no sistema público de saúde do Brasil, a opção mais viável continua sendo o voriconazol. Com relação à profilaxia de IFI em transplante de órgãos sólidos (TOS), observou-se que existem variações em função do órgão-alvo transplantado, sendo que no transplante renal (TR) nem há evidência da sua necessidade. Apesar dos azóis também serem os mais utilizados e trazerem benefícios evidentes nos transplantes de fígado (TF) e de pulmão (TP), alguns estudos atuais têm colocado as equinocandinas no mesmo patamar, encorajando mais seu uso para prevenção de IFI nesses pacientes. Conclusão: Uma vez que nos últimos 5 anos existe grande escassez de ensaios clínicos comparando diferentes profilaxias antifúngicas, novos estudos são necessários a fim de estabelecerem os protocolos mais adequados para cada condição e perfil de paciente transplantado.
- 25 January 2023
- Published by Associacao Brasileira de Transplantes de Orgaos in Brazilian Journal of Transplantation
- Vol. 26 (1)
Open AccessProfilaxia de Infecções Fúngicas em Pacientes Transplantados: O que Mudou nos Últimos Anos?
Objetivo: O presente trabalho objetivou revisar as infecções fúngicas invasivas (IFIs) e as profilaxias antifúngicas utilizadas nos últimos 20 anos em pacientes transplantados, de forma a identificar as mudanças ocorridas nesse período e discutir as condutas mais atuais. Métodos: Trata-se de uma revisão sistemática em que se utilizou a base de dados PubMed, na qual foram selecionados artigos científicos dos últimos 20 anos, abrangendo ensaios clínicos, ensaios controlados randomizados, revisões sistemáticas da literatura e metanálises. Resultados: De acordo com o presente estudo, o posaconazol e o voriconazol parecem ser as drogas antifúngicas de escolha na profilaxia de IFI em transplante de células-tronco hematopoiéticas (TCTH). Entretanto, como não há disponibilidade do posaconazol no sistema público de saúde do Brasil, a opção mais viável continua sendo o voriconazol. Com relação à profilaxia de IFI em transplante de órgãos sólidos (TOS), observou-se que existem variações em função do órgão-alvo transplantado, sendo que no transplante renal (TR) nem há evidência da sua necessidade. Apesar dos azóis também serem os mais utilizados e trazerem benefícios evidentes nos transplantes de fígado (TF) e de pulmão (TP), alguns estudos atuais têm colocado as equinocandinas no mesmo patamar, encorajando mais seu uso para prevenção de IFI nesses pacientes. Conclusão: Uma vez que nos últimos 5 anos existe grande escassez de ensaios clínicos comparando diferentes profilaxias antifúngicas, novos estudos são necessários a fim de estabelecerem os protocolos mais adequados para cada condição e perfil de paciente transplantado.
- Open Access
- 21 September 2022
- Published by Sciencedomain International in Journal of Advances in Medicine and Medical Research
- p. 156-165
Fecal Microbiota Transplant
Aims: The fecal microbiota transplantation (FMT) may be a possible solution for symptoms reduction and improvement of the clinical condition in Inflammatory bowel diseases (IBDs), such as Ulcerative Colitis (UC) and Crohn's Disease (CD). In addition to being effective in other conditions associated with disequilibrium in gastrointestinal microbiota, such as recurrent Clostridium difficile infection (RCDI) and Metabolic Syndrome (MS). The aim of this study was to review the applicability of FMT: in UC, CD, RCDI and MS. Study Design: Minireview. Place and Duration of Study: Faculty of Medical Sciences of São José dos Campos- Humanitas, between June 2021 and August 2022. Methodology: A literature search was performed in the PubMed database for clinical trial studies and review articles, published in the last 10 (ten) years. The remission of clinical conditions was established as the primary outcome and exclusion criteria was not blind or incomplete blinding studies. Based on these studies, a review regarding the applications of FMT in patients with IBD, RCDI and MS, especially its therapeutic effects, was performed. Results: In total, 53 (fifty-three) articles were selected. Studies have shown that FMT can be useful in the treatment of RCDI with cure rates ranging from 85% to 90% and represent a possible alternative to antibiotic therapy in cases of primary infection by C. difficile. FMT seems to be effective in inducing remission of UC, but its durability and long-term safety are still not well defined. Furthermore, in the treatment of Crohn's disease and metabolic syndrome, some studies show beneficial effects, but further studies are needed. Conclusion: The studies are optimistic and, even if modest, suggest that FMT has the potential for treatment and/or remission of different inflammatory and infectious conditions.
- 21 September 2022
- Published by Sciencedomain International in Journal of Advances in Medicine and Medical Research
- p. 156-165
Open AccessFecal Microbiota Transplant
Aims: The fecal microbiota transplantation (FMT) may be a possible solution for symptoms reduction and improvement of the clinical condition in Inflammatory bowel diseases (IBDs), such as Ulcerative Colitis (UC) and Crohn's Disease (CD). In addition to being effective in other conditions associated with disequilibrium in gastrointestinal microbiota, such as recurrent Clostridium difficile infection (RCDI) and Metabolic Syndrome (MS). The aim of this study was to review the applicability of FMT: in UC, CD, RCDI and MS. Study Design: Minireview. Place and Duration of Study: Faculty of Medical Sciences of São José dos Campos- Humanitas, between June 2021 and August 2022. Methodology: A literature search was performed in the PubMed database for clinical trial studies and review articles, published in the last 10 (ten) years. The remission of clinical conditions was established as the primary outcome and exclusion criteria was not blind or incomplete blinding studies. Based on these studies, a review regarding the applications of FMT in patients with IBD, RCDI and MS, especially its therapeutic effects, was performed. Results: In total, 53 (fifty-three) articles were selected. Studies have shown that FMT can be useful in the treatment of RCDI with cure rates ranging from 85% to 90% and represent a possible alternative to antibiotic therapy in cases of primary infection by C. difficile. FMT seems to be effective in inducing remission of UC, but its durability and long-term safety are still not well defined. Furthermore, in the treatment of Crohn's disease and metabolic syndrome, some studies show beneficial effects, but further studies are needed. Conclusion: The studies are optimistic and, even if modest, suggest that FMT has the potential for treatment and/or remission of different inflammatory and infectious conditions.
- Open Access
- 31 December 2020
- Published by Sociedade Brasileira de Plantas Medicinais in Revista Brasileira de Plantas Medicinais
- Vol. 22 (1) , 39-44
Ação in vitro de extratos de Arrabidaea chica sobre Candida albicans
Evidence of the inhibitory action on Candida yeasts by substances that present low or none toxicity to humans, especially substances extracted from plants already used in popular medicine, has been the intention of many researches. The objective of the present work was to determine the in vitro inhibitory activity of extracts of Arrabidaea chica on C. albicans and quantify the number of components present in the extracts. The minimum inhibitory concentration (MIC) of aqueous and hydroalcoholic extracts, autoclaved and filtered, was determined by agar dilution on twenty-five strains of C. albicans and the separation of extract components (solid-aqueous mixing), by thin layer chromatography (TLC). Both the autoclaved hydroalcoholic extract and the filtrated one inhibited all C. albicans strains, in the concentration of 20%. The autoclaved aqueous extract inhibited 84% of the strains at the concentration of 30% while the filtrated didn’t showed inhibitory effect up to a concentration of 50%. The TLC of the autoclaved hydroalcoholic extract evidenced the presence of seven components and the autoclaved aqueous one, two. The hydroalcoholic and aqueous extracts of A. chica presented inhibitory activity on C. albicans, however the hydroalcoholic extract showed superior performance and greater number of components.
- 31 December 2020
- Published by Sociedade Brasileira de Plantas Medicinais in Revista Brasileira de Plantas Medicinais
- Vol. 22 (1) , 39-44
Open AccessAção in vitro de extratos de Arrabidaea chica sobre Candida albicans
Evidence of the inhibitory action on Candida yeasts by substances that present low or none toxicity to humans, especially substances extracted from plants already used in popular medicine, has been the intention of many researches. The objective of the present work was to determine the in vitro inhibitory activity of extracts of Arrabidaea chica on C. albicans and quantify the number of components present in the extracts. The minimum inhibitory concentration (MIC) of aqueous and hydroalcoholic extracts, autoclaved and filtered, was determined by agar dilution on twenty-five strains of C. albicans and the separation of extract components (solid-aqueous mixing), by thin layer chromatography (TLC). Both the autoclaved hydroalcoholic extract and the filtrated one inhibited all C. albicans strains, in the concentration of 20%. The autoclaved aqueous extract inhibited 84% of the strains at the concentration of 30% while the filtrated didn’t showed inhibitory effect up to a concentration of 50%. The TLC of the autoclaved hydroalcoholic extract evidenced the presence of seven components and the autoclaved aqueous one, two. The hydroalcoholic and aqueous extracts of A. chica presented inhibitory activity on C. albicans, however the hydroalcoholic extract showed superior performance and greater number of components.
- 25 March 2020
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 50 (5) , e13219
Inflammatory markers in saliva for diagnosis of sepsis of hospitalizes patients
Background: Inflammatory/immunological serum markers are useful for the early detection of organ dysfunction, helping the diagnosis of sepsis. Although the detection of blood biomarkers is a standard practice, the use of noninvasive samples (eg saliva) would be beneficial.Aim: To investigate the saliva of hospitalized patients with and without sepsis and identify the levels of inflammatory markers such as C‐reactive protein (CRP), procalcitonin (PCT), interleukin 6 (IL‐6) and nitric oxide (NO).Methods: Saliva samples were collected from 26 patients in intensive care unit with diagnosis of sepsis and from 26 without sepsis (control). The levels of CRP were determined by using latex agglutination test, whereas those of procalcitonin and IL‐6 by ELISA and NO by the Griess reaction.Results: Of 26 patients with sepsis, 14 were males (54%) with a mean age of 63.81 ± 3.48 years. The control group had the same distribution for gender, with mean age 65.04 ± 4.07 years. Sepsis group showed higher salivary concentrations of CRP, PCT, IL‐6 and NO, with only levels of IL‐6 being statistically different (P = .0001).Conclusions: Patients with sepsis had significantly higher levels of IL‐6 in their saliva, suggesting that this biological sample could be useful in the diagnosis of this condition.
- 25 March 2020
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 50 (5) , e13219
Inflammatory markers in saliva for diagnosis of sepsis of hospitalizes patients
Background: Inflammatory/immunological serum markers are useful for the early detection of organ dysfunction, helping the diagnosis of sepsis. Although the detection of blood biomarkers is a standard practice, the use of noninvasive samples (eg saliva) would be beneficial.Aim: To investigate the saliva of hospitalized patients with and without sepsis and identify the levels of inflammatory markers such as C‐reactive protein (CRP), procalcitonin (PCT), interleukin 6 (IL‐6) and nitric oxide (NO).Methods: Saliva samples were collected from 26 patients in intensive care unit with diagnosis of sepsis and from 26 without sepsis (control). The levels of CRP were determined by using latex agglutination test, whereas those of procalcitonin and IL‐6 by ELISA and NO by the Griess reaction.Results: Of 26 patients with sepsis, 14 were males (54%) with a mean age of 63.81 ± 3.48 years. The control group had the same distribution for gender, with mean age 65.04 ± 4.07 years. Sepsis group showed higher salivary concentrations of CRP, PCT, IL‐6 and NO, with only levels of IL‐6 being statistically different (P = .0001).Conclusions: Patients with sepsis had significantly higher levels of IL‐6 in their saliva, suggesting that this biological sample could be useful in the diagnosis of this condition.